Inventor
MOORES SHERI
US15 patents
Patents
15 patentsUS9593164B2Mar 14, 2017
Bispecific EGFR/c-Met antibodies
JANSSEN BIOTECH INC34 citations93
US9580508B2Feb 28, 2017
Bispecific EGFR/c-Met antibodies
JANSSEN BIOTECH INC19 citations91
US9695228B2Jul 4, 2017
EGFR and c-Met fibronectin type III domain binding molecules
JANSSEN BIOTECH INC15 citations90
US9725497B2Aug 8, 2017
EGFR and C-Met fibronectin type III domain binding molecules
JANSSEN BIOTECH INC5 citations83
US9695242B2Jul 4, 2017
Bispecific EGFR/c-Met antibodies
JANSSEN BIOTECH INC8 citations83
US11459391B2Oct 4, 2022
Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
JANSSEN BIOTECH INC7 citations80
US10662235B2May 26, 2020
Cysteine engineered fibronectin type III domain binding molecules
JANSSEN BIOTECH INC4 citations72
US12304939B2May 20, 2025
EGFR and C-met fibronectin type III domain binding molecules
JANSSEN BIOTECH INC0 citations61
US10954284B2Mar 23, 2021
EGFR and c-Met fibronectin type III domain binding molecules
JANSSEN BIOTECH INC0 citations61
US12448455B2Oct 21, 2025
Combination therapies with bispecific anti-EGFR/c-met antibodies and third generation EGFR tyrosine kinase inhibitors
JANSSEN BIOTECH INC0 citations58
US11879013B2Jan 23, 2024
Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
JANSSEN BIOTECH INC0 citations58
US12215161B2Feb 4, 2025
Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
JANSSEN BIOTECH INC0 citations56
US12247077B2Mar 11, 2025
Bispecific EGFR/c-Met antibodies
JANSSEN BIOTECH INC0 citations51
US12215160B2Feb 4, 2025
Treatment of patients having c-met exon 14 skipping mutations
JANSSEN BIOTECH INC0 citations47
US12528869B2Jan 20, 2026
Treatment of non-small cell lung cancer with EGFR mutations
JANSSEN BIOTECH INC0 citations46